David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous ...

Eli Lilly’s (LLY) new weight loss pill is still in clinical trials and has not yet been approved by regulators. But that hasn ...

The weight-loss drug boom has transformed Eli Lilly (LLY), the maker of Zepbound, into the largest healthcare company in the ...

Eli Lilly's Chief Scientific Officer Dan Skovronsky says the company wants to take big swings in Alzheimer's, ALS, chronic ...

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by ...

Lilly's retatrutide shows remarkable weight loss in trials but raises concerns with side effects possibly linked to the drug like nausea and kidney stones. Read more here.

About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...

Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.

About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...